On August 24, 2018 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will webcast its management presentation at the Morgan Stanley 16th Annual Global Healthcare Conference at 9:55 a.m. Eastern Time on Wednesday, September 12, 2018 (Press release, Regeneron, AUG 24, 2018, View Source [SID1234529070]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The session may be accessed from the "Investors & Media" page of Regeneron’s website at View Source A replay of the webcast will be archived on the Company’s website and will be available for 30 days.

On August 24, 2018 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, reported that it will report its second quarter 2018 financial results on Thursday, August 30, 2018 (Press release, RedHill Biopharma, AUG 24, 2018, View Source [SID1234529054]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call on Thursday, August 30, 2018 at 8:30 a.m. EDT to review the financial results and business highlights.

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-800-263-0877; International: +1-646-828-8143; and Israel: +972-3-721-9463. The access code for the call is: 9460445.

The conference call will be broadcast live and will be available for replay on the Company’s website, View Source, for 30 days. Please access the Company’s website at least 15 minutes ahead of the conference call to register, download and install any necessary audio software.

On August 24, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse after hematopoietic stem cell transplantations (HSCT), reported that it will be announcing Financial Results for the six months ended June 30, 2018 at 7:00am CEST on Friday, August 31, 2018 (Press release, Kiadis, AUG 24, 2018, View Source [SID1234529064]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications
Tel. +31 611 096 298
[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
[email protected]

On August 24, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse after hematopoietic stem cell transplantations (HSCT), reported that it will be announcing Financial Results for the six months ended June 30, 2018 at 7:00am CEST on Friday, August 31, 2018 (Press release, Kiadis, AUG 24, 2018, View Source [SID1234529064]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information, please contact:

Kiadis Pharma:

Karl Hård, Head of IR & Communications
Tel. +31 611 096 298
[email protected]

Optimum Strategic Communications:

Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
[email protected]

On August 23, 2018 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that its Management Team will present an overview of the Company’s business at three investor conferences in September (Press release, West Pharmaceutical Services, AUG 23, 2018, View Source [SID1234529042]). Management will present at the Baird 2018 Global Healthcare Conference in New York, New York at 2:35 p.m. EDT on Wednesday, September 5, 2018; the Morgan Stanley 16th Annual Global Healthcare Conference in New York, New York at 12:20 p.m. EDT on Thursday, September 13, 2018; and at the Janney Montgomery Scott Healthcare Conference in New York, New York at 9:05 a.m. EDT on Tuesday, September 18, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast and accompanying slides of each of the presentations will be accessible from the Company’s website at www.westpharma.com/en/investors.